Assessment of Infant Outcomes After in Utero Exposure to Antiretroviral Therapy

抗逆转录病毒疗法(ART)在降低孕产妇死亡率方面产生了戏剧性的影响 在过去十年中，艾滋病毒在胎儿中的传播。应用抗逆转录病毒技术治疗母体艾滋病毒感染 在怀孕期间或减少母婴传播已成为护理的标准。 然而，预防艾滋病毒传播需要暴露怀孕的母亲和她 后代接受有效的抗逆转录病毒药物和日益复杂的治疗方案。然而， 目前批准的抗逆转录病毒药物的胎儿安全性在很大程度上是未知的。因此，在那里 是需要评估胎儿毒性的具体ART策略。考虑到压倒性的 抗逆转录病毒疗法在预防艾滋病毒传播中的益处，临床相关问题 围绕时机(例如，何时开始治疗)和特定的ART方案选择(例如， 哪种药物的组合)。这项提议的主要目的是促进胎儿安全。 为管理层制定循证建议所需的信息 将帮助临床医生和患者做出决定 制作过程。我们建议评估先天畸形和其他 产前暴露于抗逆转录病毒药物治疗后的不良妊娠结局 一群怀孕的妇女。

Antiretroviral therapy (ART) has had a dramatic impact in the reduction of maternal to fetal HIV transmission in the last decade. Use of ART to treat maternal HIV infection during pregnancy or reducing mother-to-child transmission has become standard of care. However, prevention of HIV transmission requires exposing the pregnant mother and her offspring to potent ART medications and increasingly complex treatment regimes. Yet, the fetal safety of currently approved ART medications is largely unknown. Thus, there is need to evaluate the fetal toxicity of specific ART strategies. Given the overwhelming benefits of ART in HIV transmission prevention, the clinically relevant question revolve around timing (e.g., when to initiate therapy) and specific ART regime selection (e.g., which combination of drugs). The major aim of this proposal is to contribute fetal safety information to the development of evidence-based recommendations for the management of HIV-infected pregnant women that will assist clinicians and patients in their decision making process. We propose to evaluate the risk of congenital malformations and other adverse pregnancy outcomes following antenatal exposure to ART in a prospective cohort of pregnant women.